Other ALS drug developers will look to follow Biogen/Ionis' lead in using reduction in neurofilament concentration as the basis for accelerated approval. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
